Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report by Shun Kishimoto et al.
CLINICAL REPORT
Postoperative neuroleptic malignant syndrome-like symptoms
improved with intravenous diazepam: a case report
Shun Kishimoto • Kumi Nakamura •
Toshiyuki Arai • Ogino Yukimasa • Norihiko Fukami
Received: 4 February 2013 / Accepted: 19 March 2013 / Published online: 4 April 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract A 75-year-old man who had undergone left
upper lobectomy of the lung exhibited fever and insomnia
on postoperative day (POD) 1 and muscle rigidity, auto-
nomic instability, and somnolence on POD2 after epidural
administration of droperidol and withdrawal of oral etizo-
lam. He had not been known to have any neuromuscular
diseases or psychiatric diseases, with the exception of
anxiety disorder. Brain computed tomography did not show
cerebrovascular disorders. Consultation with a neurologist
led to a suspicion of neuroleptic malignant syndrome
(NMS). Epidural droperidol was stopped and administra-
tion of dantrolene was initiated. These measures, in addi-
tion to supportive care, only partially ameliorated the
symptoms of the patient, and consciousness disturbance
developed; the patient finally became comatose on POD3.
However, intravenous diazepam (10 mg) improved his
symptoms abruptly. Subsequently, oral administration of
lorazepam (1 mg/day) was started, and his symptoms dis-
appeared within 2 days (POD5). Although NMS-like
symptoms are rarely seen in clinical practice, some factors
may induce it during the perioperative period, such as the
administration of dopamine antagonists and the cessation
of benzodiazepines. Intravenous diazepam is an effective
treatment in cases with suspected gamma-aminobutyric
acid (GABA) hypoactivity at the GABAA receptor induced
by the cessation of benzodiazepines.
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Introduction
Extrapyramidal symptoms caused by major tranquilizers is
one of the common pathological states observed during the
postoperative period. If it is observed with fever, mental
state changes, and dysautonomia, the patient is suspected to
have neuroleptic malignant syndrome (NMS). However,
benzodiazepine withdrawal can also induce similar symp-
toms. Thus, when we seek for the pathogenesis of NMS-like
symptoms of patients in the postoperative period, the drug
history should be carefully taken into consideration because
it might be the cause of the symptoms as well as anesthetics
administered intraoperatively. In this report, we described a
case of NMS-like symptoms that presented in postoperative
period and improved with intravenous diazepam.
Case report
A 75-year-old man (weight, 52 kg) diagnosed with primary
lung cancer was scheduled for left upper lobectomy of the
lung. He had undergone surgery for colon cancer under
general anesthesia 22 years previously, without perioper-
ative complications. He had not been known to have any
neuromuscular diseases or psychiatric diseases, with the
exception of anxiety disorder. He had been taking etizolam
(1.5 mg/day) for the past 15 years, in addition to antihy-
pertensive drugs. These drugs were discontinued on the day
of operation.
In the operation room, after the placement of an epidural
catheter, general anesthesia was induced using intravenous
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fentanyl (100 lg), thiamylal (250 mg), and rocuronium
(50 mg), and was maintained using sevoflurane supple-
mented with fentanyl. The operation lasted 10 h and
28 min, which was unexpectedly long, because the tumor
was highly adhesive to the surrounding tissue. Despite the
long surgery, the quality of his emergence from general
anesthesia was good; the patient responded to verbal
commands and his trachea was extubated 15 min postop-
eratively. A continuous epidural infusion of fentanyl
(16 lg/h), droperidol (0.1 mg/h), and ropivacaine (8 mg/h)
was started, and the patient was transported to the intensive
care unit (ICU) 30 min postoperatively.
On arrival at the ICU, the patient’s vital signs were
normal and he responded to verbal commands, although he
demonstrated hoarseness that was confirmed later to be
caused by unilateral recurrent laryngeal nerve palsy, which
was probably a result of the surgical procedures.
On POD1, he complained of insomnia and general
fatigue. Because of the recurrent nerve palsy, his oral
medications, including etizolam, were not given.
On POD2, he became somnolent and showed increased
muscle tone. His skin surface was cold and diaphoretic.
Respirations were almost normal, but he could not expec-
torate well. His blood pressure and pulse fluctuated from
139/82 to 197/116 mmHg and from 101 to 130 beats/min,
respectively. His temperature rose to 37.6 C, which
responded to nonsteroidal antiinflammatory drugs. Serum
creatine phosphokinase, AST/ALT, and lactate dehydro-
genase levels rose from 85 U/l, 25/14 U/l, and 336 U/l to
1,757 U/l, 38/14 U/l, and 427 U/l, respectively. Myoglo-
binuria was not observed. Brain computed tomography did
not show cerebrovascular disorders. A neurologist was
consulted, and NMS was suspected as a result of droperidol
administration. The epidural infusion of drugs, including
droperidol, was ceased immediately and the administration
of dantrolene (25 mg/day) was started via the nasogastric
tube. Intravenous infusions of landiolol (5 mg/h), nicardi-
pine (4 mg/h), and oxygen (via a face mask, 4 l/h) were
started to keep his vital signs stable.
On POD3, his muscle tone decreased slightly and the
vital signs stabilized, but the patient was comatose and
unresponsive to painful stimuli. Based on the suspicion of
benzodiazepine withdrawal syndrome, a trial dose of a
benzodiazepine was administered to the patient. The
patient became responsive to verbal commands immedi-
ately after the injection of diazepam (10 mg). After
10 min, he could sustain a sitting position and told us about
the hallucinations that he had had. Although he was still
confused, excited, and had hallucinations, his mental status
was dramatically improved (Fig. 1). Subsequently, oral
administration of lorazepam (1 mg/day) was started and his
symptoms disappeared within 2 days (POD5).
Discussion
NMS is defined as a syndrome with hyperthermia, bra-
dykinesia, rigidity, fluctuating consciousness, and auto-
nomic dysfunction and is considered to be caused by
dopamine hypoactivity. It can occur during the postop-
erative period as the result of the administration of major
tranquilizers, including droperidol [1, 2]. This syndrome
is lethal in 10 % of cases [3]; however, it is a self-limited
disorder in most cases and frequently responds to con-
servative management after cessation of the drugs.
Although hyperthermia is one of the major features of
this syndrome, the maximum temperature can be less
than 37.8 C [4]. The treatment of NMS also includes the
Fig. 1 Clinical course of the
patient: treatments, symptoms,
and vital signs. BP blood
pressure; HR heart rate.
Supportive care includes
intravenous infusions of
landiolol (5 mg/h) and of
nicardipine (1–4 mg/h) plus
oxygen (via a face mask, 4 l/h)
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withdrawal of the suspected agent and the administration
of dantrolene and bromocriptine.
Benzodiazepine withdrawal is known to induce various
symptoms, including insomnia, anxiety, and convulsion
[5, 6] and is usually treated with the administration of a
benzodiazepine [7, 8]. Several cases have been reported in
the literature in which NMS-like symptoms occurred dur-
ing withdrawal of benzodiazepines [9, 10]. In this case, the
patient had been medicated with etizolam, a thienodiaze-
pine drug that is a benzodiazepine analogue, for 15 years
until the day before surgery. Thus, benzodiazepine might
be the main cause of these NMS-like symptoms.
The symptoms presented by the patient were compatible
to NMS but not typical. If we pay attention to insomnia and
general fatigue, which had been present before the NMS-
like symptoms developed, we should consider that this
clinical course might be caused not only by droperidol
infusion but also by cessation of daily etizolam adminis-
tration because these symptoms were more likely to be
present in benzodiazepine withdrawal as ‘‘rebound
insomnia’’ [11, 12].
In the current patient, although the treatments for NMS
were effective for his muscle rigidity, autonomic dys-
function, and fever, they were not effective for his con-
sciousness disturbance and bradykinesia. A trial dose of
diazepam, however, dramatically improved the symptoms.
Benzodiazepines are one of the options for the treatment
for NMS [13], although it is not usually expected to have a
great effect. Throughout the case, although the patient did
not present the typical symptoms of NMS and benzodiaz-
epine withdrawal, the great effect of diazepam implies that
the pathogenesis of these symptoms were mainly caused by
GABAA receptor hypoactivity caused by the cessation of
etizolam. Thus, we speculate that dopamine hypoactivity
caused by droperidol induces NMS-like symptoms on the
background of GABAA receptor hypoactivity caused by
etizolam cessation. If GABAA receptor hypoactivity plays
a major role in the development of these symptoms, ben-
zodiazepine (as a GABAA receptor agonist) should be the
key treatment. In fact, there are case reports of NMS being
responsive to diazepam [14, 15].
As the etiology of NMS is widely accepted as a syn-
drome caused by dopamine hypoactivity, it seems strange
to administer a trial dose of benzodiazepine to a patient
who presents NMS-like symptoms. However, in cases of
perioperative benzodiazepine discontinuation, we can
determine the contribution of GABAA receptor hypoac-
tivity to patients who exhibit NMS-like symptoms after
general anesthesia via the administration of a benzodiaze-
pine trial dose.
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